Key information

Reproduction of the mark
Application number
202603955
Trademark text
Decnupaz
Case type
National mark
Status
03.05.2026 Uten forutgående uttalelse
Filed
27.03.2026
Priority
02.10.2025 US 99/425,467
Registration number
341658
Registered
03.05.2026
Published in the Gazette
04.05.2026
Opposition deadline
04.08.2026
Grace period start date, cf. Trademarks Act Section 37
05.08.2026
Renewal deadline
27.03.2036
Trademark category
Trademark
Type of Mark
Combined or purely figurative Mark
Goods/services (NICE class)
5
Acquired distinctiveness
No
Figurative elements (Vienna class)

01.01.25

Applicant
ImmunoGen, Inc. (US)
Owner
ImmunoGen, Inc. (US)
Agent
ZACCO NORWAY AS (NO)

List of products

Class 5
Legemidler til menneskelig bruk, nemlig farmasøytiske preparater for behandling av kreft; legemidler til menneskelig bruk, nemlig farmasøytiske preparater for behandling av onkologiske sykdommer, lidelser og tilstander.

Documents

 Download files (3)
Date
 Date Doc. No. Process Case number In/Out Journal description To/from
 03.05.2026 02-01 Saksbehandling 202603955 UT Oversendelse reg. brev (VM202603955) ZACCO NORWAY AS
 27.03.2026 01-02 Saksbehandling 202603955 INN T504623 ZACCO NORWAY AS
 27.03.2026 01-01 Saksbehandling 202603955 INN Søknadsskjema Varemerke ZACCO NORWAY AS

Priority

02.10.2025 US 99/425,467

Applicants and owners

Owners
ImmunoGen, Inc.
1 North Waukegan Road IL60064 NORTH CHICAGO US

Agent

ZACCO NORWAY AS
ZACCO NORWAY AS

Org. number: 982702887

Name and address are automatically synchronized with the Brønnøysund Register Centre.

Open in The Brønnøysund Register Centre
Postboks 488 0213 OSLO NO (OSLO Municipality, Oslo county)
Org. number: 982702887
Reference: T504623NO00

Status history

Payment history

Oppositions and appeals

No oppositions or appeals

Alteration of mark

No alteration of mark

Liens and licences

No liens or licenses registered

Gazette entries

No Gazette entries foundOnly events from 2024.03.04 and onwards are shown.